MetaVia Inc. 8-K

What Happened
MetaVia Inc. announced on April 10, 2026 (via an 8-K and attached press release) that the first patient has been dosed in Part 3 of its Phase 1 clinical trial for DA-1726, a novel dual oxyntomodulin (OXM) analog that targets both the GLP-1 (GLP1R) and glucagon (GCGR) receptors. Part 3 of the Phase 1 program consists of two 16-week titration cohorts to evaluate one-step and two-step dose‑escalation strategies aimed at safely achieving higher target doses and optimizing tolerability.

Key Details

• First patient dosed in Part 3 of the Phase 1 trial for DA-1726 (announcement date: April 10, 2026).
• DA-1726 is a dual OXM analog targeting GLP-1 and glucagon receptors (GLP1R and GCGR).
• Part 3 design: two 16-week titration cohorts to compare one-step vs. two-step dose-escalation strategies to reach higher target doses and improve tolerability.
• The announcement was made via press release (Exhibit 99.1) filed with the Form 8-K.

Why It Matters
This 8-K communicates a clinical development milestone: dosing in Part 3 signals advancement of MetaVia’s DA-1726 program and provides investors with updated information about the trial’s design and tolerability-focused dose escalation. For investors tracking clinical progress, this filing confirms the company is actively moving toward higher-dose evaluation in humans—an operational update that may precede future safety, tolerability, or efficacy readouts.